Clinical data | |
---|---|
Pronunciation | /ˌtaɪkoʊˈpleɪnɪn/ TY-koh-PLAY-nin |
Trade names | Targocid |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | Intravenous, intramuscular |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 90% (given IM) |
Protein binding | 90% to 95% |
Metabolism | Nil |
Elimination half-life | 70 to 100 hours |
Excretion | Kidney (97% unchanged) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | Variable |
Molar mass | 1564.3 to 1907.7 g/mol |
Melting point | 260 °C (500 °F) (dec.) |
| |
(what is this?) (verify) |
Teicoplanin is an semisynthetic glycopeptide antibiotic with a spectrum of activity similar to vancomycin. Its mechanism of action is to inhibit bacterial cell wall[3] peptidoglycan[4] synthesis. It is used in the prophylaxis and treatment of serious infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.[3]
Teicoplanin is marketed by Sanofi-Aventis under the trade name Targocid. Other trade names include Ticocin marketed by Cipla(India).
Oral teicoplanin has been demonstrated to be effective in the treatment of pseudomembranous colitis and Clostridioides difficile-associated diarrhoea, with comparable efficacy with vancomycin.[5]
Its strength is considered to be due to the length of the hydrocarbon chain.[6]
Teicoplanin is produced by the so-called "rare" actinobacterium Actinoplanes teichomyceticus ATCC 31121,[7] belonging to the Micromonosporaceae family. Biosynthetic pathway leading to teicoplanin, as well as the regulatory circuit governing the biosynthesis, were studied intensively in recent years allowing to construct an integrated model of the biosynthesis.[8]